Key message {#Sec1}
===========

Genetic dysfunction of ABCG2 is an important risk factor of familial early-onset hyperuricemia and gout.

Main text {#Sec2}
=========

We herein report the case of one European family with early onset of hyperuricemia/gout of which female proband was found to have pediatric-onset hyperuricemia associated with a newly identified functionally null variant allele in *ATP-binding cassette transporter G2* (*ABCG2*). Hitherto, we and other groups revealed that the dysfunction of ABCG2---a physiologically important urate exporter expressed in the kidney and intestine---raises the risk of hyperuricemia/gout \[[@CR1]--[@CR4]\]; however, there is little information on this relationship in terms of familial history of early-onset hyperuricemia/gout. Our case will emphasize the importance of *ABCG2* genotyping in the risk estimation of early onset of such excess urate-related diseases, which has the potential for clinical application in precision medicine.

The pedigree is depicted in Fig. [1](#Fig1){ref-type="fig"}a. Detailed information on each subject and related methods are available in Additional file [1](#MOESM1){ref-type="media"}. Metabolic investigation for purine metabolism suggested that hyperuricemia in two patients (the family proband II:2 and III:1) was not caused by excess production of uric acid, which led us to focus on the excretion system for urate from the body. Fig. 1Identification and functional validation of a novel dysfunctional variant p.I242T (c.725T\>C) in urate transporter ABCG2 in a family with early-onset hyperuricemia and gout. **a** Pedigree of a Czech family with early-onset hyperuricemia and gout. Electropherograms of partial sequences of *ABCG2* show the heterozygous point mutation (c.725T\>C) found in the present study; each image was a representative result. P, proband; y, years old; sU, serum urate. Hyperuricemia was defined as sU levels more than 420 μmol/L (for men) or 360 μmol/L (for women and children under 15 years) on two repeated measurements, taken at least 4 weeks apart. **b** Immunoblot of whole cell lysate samples. α-Tubulin, a loading control. WT, wild-type. **c** Intracellular localization. Confocal microscopic images were obtained 48 h after the transfection. Nuclei were stained with TO-PRO-3 iodide (gray). Bars, 10 μm. **d** Immunoblot of plasma membrane vesicles. Na^+^/K^+^ ATPase, a loading control. All analytical samples were prepared from transiently ABCG2-expressing 293A cells 48 h after plasmid transfection (**b**--**d**). **e** Urate transport activities. Data are expressed as the mean ± SD. *n* = 4. Statistical analyses for significant differences were performed using a two-sided *t*-test (\*\*, *P* \< 0.01; NS, not significantly different between groups)

To explore the possible causes of this familial hyperuricemia/gout, we addressed *ABCG2* genotypes in this family since dysfunction of ABCG2 is the strongest genetic risk factor of hyperuricemia/gout that affects urate excretion. As a result of targeted exon sequencing of *ABCG2*, two non-synonymous allelic variants of *ABCG2*---c.34G\>A (p.V12 M) and c.725T\>C (p.I242T, a novel variant)---were found in this family. There were no already-known genetic risk factors for hyperuricemia/gout such as *ABCG2* c.376C\>T (p.Q126X) and c.421C\>A (p.Q141K). Given that p.V12M variant that was only found in the subject III:2 reportedly has no effects on the expression and urate transport activity of ABCG2 \[[@CR1]\], we focused on the c.725T\>C (p.I242T) in each subject (Fig. [1](#Fig1){ref-type="fig"}a). Heterozygous mutation at c.725 T\>C was identified in all early-onset hyperuricemia/gout patients (II:2 and III:1) and one young girl (III:3). She has been on very strict purine/lactose/gluten diet for more than 10 years, which might suppress the elevation of her serum urate (sU) levels. Moreover, subjects I:2 (post-menopausal hyperuricemia woman) and III:2 (generally healthy man) who never showed clinical signs of early onset of hyperuricemia/gout were homozygous of *ABCG2* wild-type. Thus, it is conceivable that *ABCG2* c.725T\>C (p.I242T) associated with the development of early onset of hyperuricemia/gout in this family.

Next, we experimentally investigated the effect of this novel non-synonymous mutation (p.I242T) on the intracellular processing and function of ABCG2 protein. A series of biochemical analyses using transiently ABCG2-expressing mammalian cells demonstrated that the p.I242T variant had little effect on the protein level and *N*-glycosylation status of ABCG2 (Fig. [1](#Fig1){ref-type="fig"}b) and that, like ABCG2 wild-type, matured-p.I242T variant localized on the plasma membrane as a glycoprotein (Fig. [1](#Fig1){ref-type="fig"}c, d). However, functional assay revealed that contrary to the wild-type, the p.I242T variant had no ATP-dependent urate transport activity (Fig. [1](#Fig1){ref-type="fig"}e). Moreover, a cell-based urate transport assay supported that the p.I242T variant could hardly excrete urate from cells to extracellular spaces (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Thus, we concluded that the ABCG2 p.I242T variant is functionally null as an ATP-dependent urate transporter. Considering that a conserved H243 (a neighbor of I242) coordinates the γ-phosphate of ATP together with Q211 and Q126 \[[@CR5]\], structural modification caused by the local amino acid substitution (p.I242T) might affect ATP-driven conformational changes in ABCG2, resulting in the disruption of its transport activity.

In summary, we identified a novel functionally null variant of ABCG2 that related to the development of early onset of hyperuricemia/gout in a European pedigree. To the best of our knowledge, this is the first report of pedigree analysis through three generations supporting a positive relationship between familial hyperuricemia/gout history and dysfunctional allele of *ABCG2*.
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**Additional file 1.** Supplementary data
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